Search Results Search Sort by RelevanceMost Recent AMA Code Says Nov 2020 AMA Code of Medical Ethics’ Opinions Related to Risk Management Ethics Scott J. Schweikart, JD, MBE and Deborah M. Eng, MS, MA Ethical dimensions of risk management are illuminated in AMA Code content on discharge planning. AMA J Ethics. 2020;22(11):E940-944. doi: 10.1001/amajethics.2020.940. Health Law Nov 2020 How Hospital Leaders and Risk Managers Can Nurture Ethics-Driven Lawyering Norine A. McGrath, MD, Evan G. DeRenzo, PhD, John K. Kilcullen, MD, JD, MPH, and Jack Schwartz, JD Hospital lawyers’ practices shape risk management operations, influence clinicians’ morale, and affect patient care. AMA J Ethics. 2020;22(11):E933-939. doi: 10.1001/amajethics.2020.933. Medicine and Society Oct 2023 What Might Aducanumab Teach Us About Clinicians’ Judgment About Whether to Recommend Emerging Alzheimer’s Interventions? Adam W. Burroughs, MD and Lewis P. Krain, MD Ethics questions about care of patients with AD could influence clinicians’ judgment about whether and when to recommend aducanumab. AMA J Ethics. 2023;25(10):E777-782. doi: 10.1001/amajethics.2023.777. Viewpoint Aug 2002 A Better Perspective: Dr. Alan Heins and the CATCH Program Susanna Smith Virtual Mentor. 2002;4(8):244-245. doi: 10.1001/virtualmentor.2002.4.8.prol1-0208. State of the Art and Science Nov 2001 Commemorative Issue: Genetic Differences - Unfair or Only Unfortunate? Faith Lagay, PhD Virtual Mentor. 2001;3(11):414-417. doi: 10.1001/virtualmentor.2001.3.11.gnth1-0111. Case and Commentary Jun 2002 Right to Discontinue Treatment, Commentary 1 Jim Kirkpatrick, MD Virtual Mentor. 2002;4(6):159-163. doi: 10.1001/virtualmentor.2002.4.6.ccas1-0206. Case and Commentary Jun 2002 Right to Discontinue Treatment, Commentary 2 Erin Egan, MD, JD and Kayhan Parsi, JD, PhD Virtual Mentor. 2002;4(6):164-168. doi: 10.1001/virtualmentor.2002.4.6.ccas1-0206. State of the Art and Science Feb 2001 Gene Therapy or Genetic Enhancement: Does It Make a Difference? Faith Lagay, PhD Virtual Mentor. 2001;3(2):37-39. doi: 10.1001/virtualmentor.2001.3.2.gnth1-0102. State of the Art and Science Nov 2008 Managing Prehypertension David S. Hatem, MD Strategies to manage hypertension and prehypertension are available. Virtual Mentor. 2008;10(11):735-739. doi: 10.1001/virtualmentor.2008.10.11.cprl1-0811. Case and Commentary Feb 2007 Turning Off an Implanted Life-Saving Device, Commentary 2 Katrina A. Bramstedt, PhD Medical technology presents a new ethical question in the case of a patient with a left ventricular assist device who, when informed that he has pneumonia and is ineligible for a heart transplant, asks that the LVAD be turned off. Virtual Mentor. 2007;9(2):96-98. doi: 10.1001/virtualmentor.2007.9.2.ccas2-0702. Pagination First page « First Previous page ‹ Previous Page 1 Page 2 Page 3 Current page 4 Page 5 Page 6 Page 7 Page 8 Next page Next › Last page Last »
AMA Code Says Nov 2020 AMA Code of Medical Ethics’ Opinions Related to Risk Management Ethics Scott J. Schweikart, JD, MBE and Deborah M. Eng, MS, MA Ethical dimensions of risk management are illuminated in AMA Code content on discharge planning. AMA J Ethics. 2020;22(11):E940-944. doi: 10.1001/amajethics.2020.940.
Health Law Nov 2020 How Hospital Leaders and Risk Managers Can Nurture Ethics-Driven Lawyering Norine A. McGrath, MD, Evan G. DeRenzo, PhD, John K. Kilcullen, MD, JD, MPH, and Jack Schwartz, JD Hospital lawyers’ practices shape risk management operations, influence clinicians’ morale, and affect patient care. AMA J Ethics. 2020;22(11):E933-939. doi: 10.1001/amajethics.2020.933.
Medicine and Society Oct 2023 What Might Aducanumab Teach Us About Clinicians’ Judgment About Whether to Recommend Emerging Alzheimer’s Interventions? Adam W. Burroughs, MD and Lewis P. Krain, MD Ethics questions about care of patients with AD could influence clinicians’ judgment about whether and when to recommend aducanumab. AMA J Ethics. 2023;25(10):E777-782. doi: 10.1001/amajethics.2023.777.
Viewpoint Aug 2002 A Better Perspective: Dr. Alan Heins and the CATCH Program Susanna Smith Virtual Mentor. 2002;4(8):244-245. doi: 10.1001/virtualmentor.2002.4.8.prol1-0208.
State of the Art and Science Nov 2001 Commemorative Issue: Genetic Differences - Unfair or Only Unfortunate? Faith Lagay, PhD Virtual Mentor. 2001;3(11):414-417. doi: 10.1001/virtualmentor.2001.3.11.gnth1-0111.
Case and Commentary Jun 2002 Right to Discontinue Treatment, Commentary 1 Jim Kirkpatrick, MD Virtual Mentor. 2002;4(6):159-163. doi: 10.1001/virtualmentor.2002.4.6.ccas1-0206.
Case and Commentary Jun 2002 Right to Discontinue Treatment, Commentary 2 Erin Egan, MD, JD and Kayhan Parsi, JD, PhD Virtual Mentor. 2002;4(6):164-168. doi: 10.1001/virtualmentor.2002.4.6.ccas1-0206.
State of the Art and Science Feb 2001 Gene Therapy or Genetic Enhancement: Does It Make a Difference? Faith Lagay, PhD Virtual Mentor. 2001;3(2):37-39. doi: 10.1001/virtualmentor.2001.3.2.gnth1-0102.
State of the Art and Science Nov 2008 Managing Prehypertension David S. Hatem, MD Strategies to manage hypertension and prehypertension are available. Virtual Mentor. 2008;10(11):735-739. doi: 10.1001/virtualmentor.2008.10.11.cprl1-0811.
Case and Commentary Feb 2007 Turning Off an Implanted Life-Saving Device, Commentary 2 Katrina A. Bramstedt, PhD Medical technology presents a new ethical question in the case of a patient with a left ventricular assist device who, when informed that he has pneumonia and is ineligible for a heart transplant, asks that the LVAD be turned off. Virtual Mentor. 2007;9(2):96-98. doi: 10.1001/virtualmentor.2007.9.2.ccas2-0702.